Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aspirin/prednisone therapy ineffective in fetal loss prevention, study suggests.

This article was originally published in The Tan Sheet

Executive Summary

ASPIRIN/PREDNISONE THERAPY "NOT EFFECTIVE IN PROMOTING LIVE BIRTH" in women who have tested positive for auto-antibodies and who have suffered from past unexplained recurrent fetal loss, according to a study published in the July 17 New England Journal of Medicine. In addition, the dual treatment appears to increase the risk of premature birth and may be responsible for side effects including hypertension and diabetes mellitus, Carl Laskin, MD, University of Toronto, et al. conclude. The study was funded by the Medical Research Council of Canada.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS087309

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel